Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 7/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 4/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4650224 | 0.90 | GAA (0.70) | GAAHSD17B10NPC1ADORA2BTSHR | |
| SCHEMBL4647287 | 0.88 | GAA (0.84) | GAAHSD17B10NPC1ADORA2BTSHR | |
| SCHEMBL4744658 | 0.86 | GAA (0.66) | GAAHSD17B10NPC1ADORA2BTSHR | |
| SCHEMBL13745523 | 0.85 | GAA (0.76) | GAAHSD17B10NPC1TSHRHTT | |
| SCHEMBL6406676 | 0.85 | GAA (0.73) | GAAHSD17B10NPC1ADORA2BTSHR | |
| SCHEMBL4647892 | 0.82 | GAA (0.70) | GAAHSD17B10NPC1ADORA2BTSHR | |
| SCHEMBL4648311 | 0.79 | GAA (1.00) | GAAHSD17B10NPC1ADORA2BTSHR | |
| SCHEMBL4647903 | 0.78 | GAA (0.76) | GAAHSD17B10NPC1ADORA2BTSHR | |
| SCHEMBL4743523 | 0.77 | GAA (0.57) | GAAHSD17B10NPC1ADORA2BTSHR | |
| SCHEMBL6404869 | 0.76 | GAA (0.56) | GAAHSD17B10NPC1ADORA2BTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675834-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2008-08-27 | — | — | EP | claimed |
| EP-1675834-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2006-07-05 | — | — | EP | claimed |
| US-20050282838-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2005-12-22 | — | — | US | claimed |
| WO-2005037799-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2005-04-28 | — | — | WO | claimed |
| US-20050282838-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282838-A1 | Compounds, compositions, and methods | PCNA, MKI67, TP53 | GAA 349/4885HSD17B10 1067/4885NPC1 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.